Arc Nouvel Archives - Arc Nouvel

16 Jul

Articles
No Comments

The Missing Majority: Why Older Adults Remain the Weakest Link in Oncology Trial Evidence

Over the past decade, oncology has achieved a level of biological precision that would have been difficult to imagine even twenty years ago. Molecular stratification has redefined disease taxonomy, biomarker-driven therapies have reshaped treatment algorithms, and adaptive trial designs have...

16 Jun

Articles
No Comments

GLP-1 Receptor Agonists and Cancer: Separating Signal from Noise

The GLP-1 and cancer debate is increasingly being discussed not only as a safety question, but also as a prevention and pharmacovigilance question. Recent academic studies are examining whether glucagon-like peptide-1 receptor agonists are associated with cancer risk among adults...

13 May

Articles
No Comments

Precision Medicine From Biology to Bedside With Dr. Wafik El-Deiry

In the early 1990s, Wafik El-Deiry helped identify a gene that explained one of cancer biology’s most essential acts of restraint: how a damaged cell stops dividing. The gene was p21, also known as WAF1. At the time, gene names...

20 Apr

Articles
No Comments

Rethinking the myth of the “Dark Side” With Dr. Lokesh Jain

The transition from clinical practice or a research career to the pharmaceutical industry is often met with the perception of having “gone to the dark side.” This sentiment reflects a traditional view that working in industry somehow represents a departure...

14 Apr

Articles
No Comments

What It Takes to Lead at the Top: Dr. Roy Baynes and the Discipline of Meaningful Medicine

There is one idea that seems to sit at the center of Dr. Roy Baynes’s career, and perhaps at the center of his leadership philosophy too: important work must remain anchored to human benefit. In an era that can sometimes...

20 Mar

Articles
No Comments

What It Takes to Lead at the Top: Jill DeSimone on Purpose, Trust, and the Human Side of Pharma Leadership

In every industry, there are executives who build impressive careers. And then there are leaders whose careers become a study in impact: not only in terms of business performance, but in the lives they shape, the standards they set, and...

26 Feb

Articles
No Comments

Who is Arc Nouvel: Dr. Vivian Li on Strategy, Risk, and Value in Clinical Development

Across the drug development lifecycle, including pre-IND readiness, early clinical transitions, manufacturing evolution, and regulatory engagement, biotech and pharmaceutical companies turn to Arc Nouvel for specialized guidance. In oncology and beyond, the firm’s clients are often navigating early clinical decisions...

26 Feb

Articles
No Comments

Who is Arc Nouvel: Dr. Robert Charnas on Regulatory Strategy, Patient-Focused Development, and the Discipline to Stop

Arc Nouvel is a boutique consulting firm that supports pharmaceutical, biotechnology, and investment clients with end-to-end clinical development solutions, strategic consulting, operational support, and executive coaching across early- to late-phase programs. But the firm’s real advantage lies in the experience...

24 Feb

Articles
No Comments

Who Is Arc Nouvel? A Conversation with Dr. Gavin Liu on Cell Therapy CMC Strategy and GMP Manufacturing

Arc Nouvel works with biotechnology and pharmaceutical companies at inflection points, pre-IND preparation, early clinical transitions, manufacturing evolution, and regulatory engagement. At these moments, scientific promise alone is not enough. What determines whether a therapy advances efficiently or stalls under...

02 Feb

Articles
No Comments

Rethinking the “Dark Side”: Interview with Dr. Scott Pruitt

For decades, a familiar phrase has echoed through academic hallways and hospital corridors whenever a physician-scientist announces a move into industry: “going to the dark side”. The words are often delivered with a wry smile or a half-joking warning, but...

Arc Nouvel

The Missing Majority: Why Older Adults Remain the Weakest Link in Oncology Trial Evidence

GLP-1 Receptor Agonists and Cancer: Separating Signal from Noise

Precision Medicine From Biology to Bedside With Dr. Wafik El-Deiry

Rethinking the myth of the “Dark Side” With Dr. Lokesh Jain

What It Takes to Lead at the Top: Dr. Roy Baynes and the Discipline of Meaningful Medicine

What It Takes to Lead at the Top: Jill DeSimone on Purpose, Trust, and the Human Side of Pharma Leadership

Who is Arc Nouvel: Dr. Vivian Li on Strategy, Risk, and Value in Clinical Development

Who is Arc Nouvel: Dr. Robert Charnas on Regulatory Strategy, Patient-Focused Development, and the Discipline to Stop

Who Is Arc Nouvel? A Conversation with Dr. Gavin Liu on Cell Therapy CMC Strategy and GMP Manufacturing

Rethinking the “Dark Side”: Interview with Dr. Scott Pruitt

Contact us Now

Menu

Contact Us

Follow Us